215 related articles for article (PubMed ID: 18775810)
1. Effects of the JAK2 inhibitor, AZ960, on Pim/BAD/BCL-xL survival signaling in the human JAK2 V617F cell line SET-2.
Gozgit JM; Bebernitz G; Patil P; Ye M; Parmentier J; Wu J; Su N; Wang T; Ioannidis S; Davies A; Huszar D; Zinda M
J Biol Chem; 2008 Nov; 283(47):32334-43. PubMed ID: 18775810
[TBL] [Abstract][Full Text] [Related]
2. AZ960, a novel Jak2 inhibitor, induces growth arrest and apoptosis in adult T-cell leukemia cells.
Yang J; Ikezoe T; Nishioka C; Furihata M; Yokoyama A
Mol Cancer Ther; 2010 Dec; 9(12):3386-95. PubMed ID: 21159615
[TBL] [Abstract][Full Text] [Related]
3. The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.
Mazzacurati L; Lambert QT; Pradhan A; Griner LN; Huszar D; Reuther GW
Oncotarget; 2015 Nov; 6(37):40141-57. PubMed ID: 26472029
[TBL] [Abstract][Full Text] [Related]
4. RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis.
Winter PS; Sarosiek KA; Lin KH; Meggendorfer M; Schnittger S; Letai A; Wood KC
Sci Signal; 2014 Dec; 7(357):ra122. PubMed ID: 25538080
[TBL] [Abstract][Full Text] [Related]
5. Bim and Mcl-1 exert key roles in regulating JAK2V617F cell survival.
Rubert J; Qian Z; Andraos R; Guthy DA; Radimerski T
BMC Cancer; 2011 Jan; 11():24. PubMed ID: 21247487
[TBL] [Abstract][Full Text] [Related]
6. Activation of a non-genomic Pim-1/Bad-Pser75 module is required for an efficient pro-survival effect of Bcl-xL induced by androgen in LNCaP cells.
Kumar JK; Ping RY; Teong HF; Goh S; Clément MV
Int J Biochem Cell Biol; 2011 Apr; 43(4):594-603. PubMed ID: 21187157
[TBL] [Abstract][Full Text] [Related]
7. Deregulation of apoptosis-related genes is associated with PRV1 overexpression and JAK2 V617F allele burden in Essential Thrombocythemia and Myelofibrosis.
Tognon R; Gasparotto EP; Neves RP; Nunes NS; Ferreira AF; Palma PV; Kashima S; Covas DT; Santana M; Souto EX; Zanichelli MA; Simões BP; de Souza AM; Castro FA
J Hematol Oncol; 2012 Feb; 5():2. PubMed ID: 22300941
[TBL] [Abstract][Full Text] [Related]
8. Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor.
Quintás-Cardama A; Manshouri T; Estrov Z; Harris D; Zhang Y; Gaikwad A; Kantarjian HM; Verstovsek S
Invest New Drugs; 2011 Oct; 29(5):818-26. PubMed ID: 20372971
[TBL] [Abstract][Full Text] [Related]
9. Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2
Hu M; Xu C; Yang C; Zuo H; Chen C; Zhang D; Shi G; Wang W; Shi J; Zhang T
J Exp Clin Cancer Res; 2019 Feb; 38(1):49. PubMed ID: 30717771
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo characterization of SGI-1252, a small molecule inhibitor of JAK2.
Ahmed KB; Warner SL; Chen A; Gourley ES; Liu X; Vankayalapati H; Nussenzveig R; Prchal JT; Bearss DJ; Parker CJ
Exp Hematol; 2011 Jan; 39(1):14-25. PubMed ID: 20934482
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of B7-H3 augments anti-apoptosis of colorectal cancer cells by Jak2-STAT3.
Zhang T; Jiang B; Zou ST; Liu F; Hua D
World J Gastroenterol; 2015 Feb; 21(6):1804-13. PubMed ID: 25684945
[TBL] [Abstract][Full Text] [Related]
12. Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors.
Waibel M; Solomon VS; Knight DA; Ralli RA; Kim SK; Banks KM; Vidacs E; Virely C; Sia KC; Bracken LS; Collins-Underwood R; Drenberg C; Ramsey LB; Meyer SC; Takiguchi M; Dickins RA; Levine R; Ghysdael J; Dawson MA; Lock RB; Mullighan CG; Johnstone RW
Cell Rep; 2013 Nov; 5(4):1047-59. PubMed ID: 24268771
[TBL] [Abstract][Full Text] [Related]
13. Lactogens promote beta cell survival through JAK2/STAT5 activation and Bcl-XL upregulation.
Fujinaka Y; Takane K; Yamashita H; Vasavada RC
J Biol Chem; 2007 Oct; 282(42):30707-17. PubMed ID: 17728251
[TBL] [Abstract][Full Text] [Related]
14. Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805.
Baffert F; Régnier CH; De Pover A; Pissot-Soldermann C; Tavares GA; Blasco F; Brueggen J; Chène P; Drueckes P; Erdmann D; Furet P; Gerspacher M; Lang M; Ledieu D; Nolan L; Ruetz S; Trappe J; Vangrevelinghe E; Wartmann M; Wyder L; Hofmann F; Radimerski T
Mol Cancer Ther; 2010 Jul; 9(7):1945-55. PubMed ID: 20587663
[TBL] [Abstract][Full Text] [Related]
15. Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells.
Fiskus W; Verstovsek S; Manshouri T; Rao R; Balusu R; Venkannagari S; Rao NN; Ha K; Smith JE; Hembruff SL; Abhyankar S; McGuirk J; Bhalla KN
Clin Cancer Res; 2011 Dec; 17(23):7347-58. PubMed ID: 21976548
[TBL] [Abstract][Full Text] [Related]
16. JAK2/STAT5/Bcl-xL signalling is essential for erythropoietin-mediated protection against apoptosis induced in PC12 cells by the amyloid β-peptide Aβ25-35.
Ma R; Hu J; Huang C; Wang M; Xiang J; Li G
Br J Pharmacol; 2014 Jul; 171(13):3234-45. PubMed ID: 24597613
[TBL] [Abstract][Full Text] [Related]
17. Homoharringtonine affects the JAK2-STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells.
Tong H; Ren Y; Zhang F; Jin J
Eur J Haematol; 2008 Oct; 81(4):259-66. PubMed ID: 18616510
[TBL] [Abstract][Full Text] [Related]
18. Constitutively activated FLT3 phosphorylates BAD partially through pim-1.
Kim KT; Levis M; Small D
Br J Haematol; 2006 Sep; 134(5):500-9. PubMed ID: 16869825
[TBL] [Abstract][Full Text] [Related]
19. Concomitant inactivation of the epidermal growth factor receptor, phosphatidylinositol 3-kinase/Akt and Janus tyrosine kinase 2/signal transducer and activator of transcription 3 signalling pathways in cardiotoxin III-treated A549 cells.
Su JC; Lin KL; Chien CM; Chuang PW; Chang LS; Lin SR
Clin Exp Pharmacol Physiol; 2010 Aug; 37(8):833-40. PubMed ID: 20456425
[TBL] [Abstract][Full Text] [Related]
20. Bcl-xL represents a therapeutic target in Philadelphia negative myeloproliferative neoplasms.
Petiti J; Lo Iacono M; Rosso V; Andreani G; Jovanovski A; Podestà M; Lame D; Gobbi M; Fava C; Saglio G; Frassoni F; Cilloni D
J Cell Mol Med; 2020 Sep; 24(18):10978-10986. PubMed ID: 32790151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
